Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT

Study Overview
=================
Brief Summary
-----------------
Myocardial perfusion scintigraphy is to evaluate coronary perfusion as well as heart muscle function. This examination takes place in two stages, one imaging at rest and one after a cardiac stress caused. This stress can be triggered as a first-line stress test. A pharmacological stress is proposed when stress test is not possible or contraindicated, Several drugs have a marketing authorization in this indication (adenosine, dipyridamole, regadenoson, dobutamine). Among them, the regadenoson is the most recent molecule. Marketed in France since 2013, it would allow a reduction of undesirable effects compared to other agents, especially adenosine. It is simple and quick to use thanks to a single dose administration. However, its cost is nearly 30 times higher than dipyridamole. In the investigational center, dipyridamole is currently the first-line pharmacological stress agent, whereas regadenoson is reserved for a limited number of doses, the indication of which must be justified (asthmatic patient or with severe COPD). Few studies in the literature specifically compare these two pharmacological agents (examination time, cost, tolerance) and the opinion on the use of regadenoson in the service is limited.

Official Title
-----------------
Descriptive Study Comparing Regadenoson Versus Dipyridamole in Use as Pharmacological Stress Agent Before a Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (SPECT)

Conditions
-----------------
Myocardial Perfusion Imaging

Intervention / Treatment
-----------------
* Other: collect examination time, functional and clinical tolerability


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult ≥ 18 years Myocardial scintigraphy by pharmacological stress agent Used molecules = Dipyridamole or Regadenoson Exclusion Criteria: Physical stress test by single or mixed effort (associating pharmacological stress) Pharmacological agent used = Adenosine Inclusion in the ERCAD protocol Double isotope protocol Patient refusal due to study information

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dipyridamole<br>stress test impossible or contraindicated (first intention) | Other: collect examination time, functional and clinical tolerability<br>* Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist<br>|
| Regadenoson<br>stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention) | Other: collect examination time, functional and clinical tolerability<br>* Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of the test | Evaluate the time savings from the use of regadenoson versus dipyridamole by comparing the duration of the test. | 24 hours (Visit 1: During the examen) |